Operator

Good afternoon, and welcome to Verastem Oncology's VS-7375 R&D Update Conference Call. My name is Towanda, and I will be your call operator today. Please note, this event is being recorded. [Operator Instructions] I will now turn the call over to Julissa Viana, Senior Vice President of Corporate Communications, Investor Relations and Patient Efficacy at Verastem Oncology. Ma'am, you may begin.

Julissa Viana
Vice President of Corporate Communications & Investor Relations

Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss our potential best-in-class, highly selective oral KRAS G12D on/off inhibitor, VS-7375. We will share progress from our Target-D clinical development program, including preliminary data from the Target-D 101 dose escalation and dose expansion trial. This afternoon, we issued a press release detailing these results, along with a slide presentation that we will reference during our call today. Both are available on the Investor Relations section of our website.

Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may